To observe the effect of the Composite Blister Beetle Capsule in the treatment of perioperative lung cancer, and to discuss the regulation of immunity. Methods:A total of 90 perioperative lung cancer who were admitted to our department from August 2015-January 2016, were randomly divided into control group and observation group, 45 cases in each group. The control group, glucose injection 250 mL intravenous injection, twice a day for 15 days. Observation group were given Composite Blister Beetle Capsule twice a day. After 15 days’treatment, the clinical efficacy of the same treatment, all immune factors score, adverse drug reactions, clinical benefit analysis and serum IL-2, IL-6, IL-10 and TNF-α level changes were evaluated. Results:1）After the treatment, the observation group’s effective rate was 88.89％, the control group 77.78, the differences were statistically significant between the two groups(P<0.05)；2) Before treatment, comparison of each two groups of patients,’immune function has no statistically significant difference(P>0.05), after 15 days’treatment, observation group’s immunized kinetic energy slightly improved, but the treatment experienced no changes compared with the control group, the difference was statistically significant (P<0.05); 3) During the treatment, 2 groups of patients showed different adverse reactions, such as abdominal pain, diarrhea, nausea, vomiting, white blood cells, platelets, hemoglobin and reduction treatment. There was 1 case (4.44%) in control group, but two cases (4.44%) in observation group, the difference was not statistically significant, the drug does not increase side effects (P>0.05). The observation group has higher stability rate than control group in KPS and body weight change (P<0.05); 4) Before treatment, the comparison of two groups of patients in plasma IL-2, IL-6, IL-10 and TNF-α level showed no different (P>0.05). After 15 days’treatment, the index decreased, but the observation group decreased more significantly. Conclusion:Composite Blister Beetle Capsule can improve the immunity of lung cancer patients with significant clinical effect and not obvious side effect, which is worthy of clinical promotion.